- Home
- NCMI vs BCYC Comparison
NCMI vs BCYC Comparison
Compare NCMI & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCMI
- BCYC
- Stock Information
- Founded
- NCMI 2005
- BCYC 2009
- Country
- NCMI United States
- BCYC United Kingdom
- Employees
- NCMI N/A
- BCYC N/A
- Industry
- NCMI Advertising
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- NCMI Consumer Discretionary
- BCYC Health Care
- Exchange
- NCMI Nasdaq
- BCYC Nasdaq
- Market Cap
- NCMI 458.3M
- BCYC 529.8M
- IPO Year
- NCMI 2007
- BCYC 2019
- Fundamental
- Price
- NCMI $4.54
- BCYC $7.10
- Analyst Decision
- NCMI Strong Buy
- BCYC Buy
- Analyst Count
- NCMI 4
- BCYC 12
- Target Price
- NCMI $7.00
- BCYC $22.91
- AVG Volume (30 Days)
- NCMI 605.4K
- BCYC 261.8K
- Earning Date
- NCMI 08-05-2025
- BCYC 08-08-2025
- Dividend Yield
- NCMI 2.62%
- BCYC N/A
- EPS Growth
- NCMI N/A
- BCYC N/A
- EPS
- NCMI N/A
- BCYC N/A
- Revenue
- NCMI $235,300,000.00
- BCYC $19,281,000.00
- Revenue This Year
- NCMI $7.90
- BCYC $7.35
- Revenue Next Year
- NCMI $13.36
- BCYC N/A
- P/E Ratio
- NCMI N/A
- BCYC N/A
- Revenue Growth
- NCMI 13.34
- BCYC N/A
- 52 Week Low
- NCMI $4.12
- BCYC $6.10
- 52 Week High
- NCMI $7.60
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- NCMI 47.48
- BCYC 37.11
- Support Level
- NCMI $4.14
- BCYC $7.25
- Resistance Level
- NCMI $4.49
- BCYC $7.68
- Average True Range (ATR)
- NCMI 0.21
- BCYC 0.42
- MACD
- NCMI -0.01
- BCYC -0.07
- Stochastic Oscillator
- NCMI 51.95
- BCYC 12.80
About NCMI National CineMedia Inc.
National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.